Amsterdam and Lyon, 19 November 2026

EXOR TO RAISE ITS STAKE IN BIOMÉRIEUX

- **Exor becomes a long-term investor in bioMérieux**
- **Institut Mérieux remains firmly committed to bioMérieux as its majority shareholder**
- **Exor maintains a significant shareholding in Institut Mérieux, continuing the relationship established in 2022**

Exor N.V. ("Exor") and Institut Mérieux today announce that Exor will increase its direct stake in bioMérieux, a world leader in the field of in vitro diagnostics, from 3.87% to 8.53%, reflecting its confidence in the company.

Exor will receive the bioMérieux shares through a reduction of Institut Mérieux's share capital, in exchange for part of its Institut Mérieux shares.

Following completion, which is expected in December 2026, subject to the creditor objection period and formal approval by Institut Mérieux's shareholders, Exor will hold 8.53% of bioMérieux's share capital and 5.35% of its voting rights. Institut Mérieux will remain bioMérieux's majority shareholder, with 55.24% of the share capital and 68.67% of the voting rights. After the transaction, Exor will hold 5.02% of Institut Mérieux's share capital and 2.58% of its voting rights.

Exor has been a shareholder of Institut Mérieux since 2022 and a direct shareholder of bioMérieux since 2025. bioMérieux's Board of Directors is expected to propose the appointment of Benoît Ribadeau-Dumas as Exor's representative at its next Annual General Meeting. He is already a board member of Institut Mérieux and a non-voting observer on bioMérieux's Board. Institut Mérieux's governance will be unchanged.

Exor and the Mérieux family do not intend to act in concert with respect to bioMérieux.

Alexandre Mérieux, Vice-Chairman of the Board of Directors of Institut Mérieux and Chairman of the Board of Directors of bioMérieux, said: *"Over the years, we have developed a strong relationship with Exor built on trust, close dialogue with John Elkann and Benoît Ribadeau-Dumas' valuable contribution to our Board. Exor's continued presence on Institut Mérieux's Board is a sign of our commitment to working closely together. Today, we welcome Exor's increased direct stake in bioMérieux, which reflects our mutual confidence in the company's strength, while its continued holding in Institut Mérieux reaffirms its support for*

Investor Relations Exor
Tel. +31 (0)20 240 2 222
ir@exor.com
Media Exor
Tel. +31 (0)20 240 2 221
media@exor.com

Media Institut Mérieux
Tel. : +33 (0)4 78 87 70 70
communication@institut-merieux.com

Investor Relations bioMérieux
Tel. +33 (0)4 78 87 20 00
investor.relations@biomerieux.com
Media bioMérieux
Tel. +33 (0)4 78 87 20 00
media@biomerieux.com

the Group. As bioMérieux's majority shareholder, Institut Mérieux will continue to support its growth and innovation priorities. The same vision guides the development of all our companies, united by a common ambition to advance public health worldwide."

John Elkann, Chief Executive Officer of Exor, said: *"Since 2022, our investment in Institut Mérieux has given us a close view of the Mérieux family's entrepreneurial culture and commitment to public health. We remain a committed shareholder of the Group and are very pleased to further increase our existing stake in bioMérieux, a company we know well, greatly value for its leadership in diagnostics and want to support over the long term."*

Pierre Boulud, Chief Executive Officer of bioMérieux, added*: "Less than 2 years after first investing in the company, Exor's decision to increase its stake in bioMérieux is a strong vote of confidence in our strategy, our growth potential and our ability to create value. This long-term perspective is one we deeply value. Institut Mérieux will remain our majority shareholder. The stability and support that come with the Mérieux's family ownership have always been a strength for bioMérieux and are particularly valuable in today's changing environment."*

About Exor

Exor N.V. (AEX: EXO) has been building great companies since its foundation by the Agnelli Family. For more than a century, Exor has made successful investments worldwide, applying a culture that combines entrepreneurial spirit and financial discipline. Its portfolio is principally made up of companies in which Exor is the largest shareholder including Ferrari, Philips, CNH and Stellantis.

About Institut Mérieux

For nearly 130 years, Institut Mérieux has been committed to serving global public health. The Group oversees companies with complementary activities in in vitro diagnostics, food safety, immunotherapy, and health investments. It is the majority shareholder in four companies that form the core of its bioindustrial group: bioMérieux, Mérieux NutriSciences, Transgene, and Mérieux Equity Partners. The Group brings together 26,000 people in more than 50 countries, while maintaining a strong base in France. Institut Mérieux is also a committed shareholder of two other companies, Ceva and OXB.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Investor Relations Exor
Tel. +31 (0)20 240 2 222
ir@exor.com
Media Exor
Tel. +31 (0)20 240 2 221
media@exor.com

Media Institut Mérieux
Tel. : +33 (0)4 78 87 70 70
communication@institut-merieux.com

Investor Relations bioMérieux
Tel. +33 (0)4 78 87 20 00
investor.relations@biomerieux.com
Media bioMérieux
Tel. +33 (0)4 78 87 20 00
media@biomerieux.com